Home > Publications Database > Facilitating the use of the target product profile in academic research: a systematic review. > print

001     271064
005     20250127091643.0
024 7 _ |a 10.1186/s12967-024-05476-1
|2 doi
024 7 _ |a pmid:39075460
|2 pmid
024 7 _ |a pmc:PMC11288132
|2 pmc
037 _ _ |a DZNE-2024-00936
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ahmed Ibnidris Elsiddig, Aliaa
|0 P:(DE-2719)9002584
|b 0
|e First author
|u dzne
245 _ _ |a Facilitating the use of the target product profile in academic research: a systematic review.
260 _ _ |a London
|c 2024
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723107110_2208
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The Target Product Profile (TPP) is a tool used in industry to guide development strategies by addressing user needs and fostering effective communication among stakeholders. However, they are not frequently used in academic research, where they may be equally useful. This systematic review aims to extract the features of accessible TPPs, to identify commonalities and facilitate their integration in academic research methodology.We searched peer-reviewed papers published in English developing TPPs for different products and health conditions in four biomedical databases. Interrater agreement, computed on random abstract and paper sets (Cohen's Kappa; percentage agreement with zero tolerance) was > 0.91. We interviewed experts from industry contexts to gain insight on the process of TPP development, and extracted general and specific features on TPP use and structure.138 papers were eligible for data extraction. Of them, 92% (n = 128) developed a new TPP, with 41.3% (n = 57) focusing on therapeutics. The addressed disease categories were diverse; the largest (47.1%, n = 65) was infectious diseases. Only one TPP was identified for several fields, including global priorities like dementia. Our analyses found that 56.5% of papers (n = 78) was authored by academics, and 57.8% of TPPs (n = 80) featured one threshold level of product performance. The number of TPP features varied widely across and within product types (n = 3-44). Common features included purpose/context of use, shelf life for drug stability and validation aspects. Most papers did not describe the methods used to develop the TPP. We identified aspects to be taken into account to build and report TPPs, as a starting point for more focused initiatives guiding use by academics.TPPs are used in academic research mostly for infectious diseases and have heterogeneous features. Our extraction of key features and common structures helps to understand the tool and widen its use in academia. This is of particular relevance for areas of notable unmet needs, like dementia. Collaboration between stakeholders is key for innovation. Tools to streamline communication such as TPPs would support the development of products and services in academia as well as industry.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Methodology
|2 Other
650 _ 7 |a Quality by design
|2 Other
650 _ 7 |a TPP
|2 Other
650 _ 7 |a Target product profile
|2 Other
650 _ 7 |a Translational methods
|2 Other
650 _ 7 |a Translational research
|2 Other
650 _ 2 |a Academia
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Biomedical Research
|2 MeSH
700 1 _ |a Liaskos, Nektarios
|0 P:(DE-2719)9002840
|b 1
|u dzne
700 1 _ |a Eldem, Ece
|0 P:(DE-2719)9002949
|b 2
|u dzne
700 1 _ |a Gunn, Angus
|b 3
700 1 _ |a Streffer, Johannes
|b 4
700 1 _ |a Gold, Michael
|b 5
700 1 _ |a Rea, Mike
|b 6
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 7
|u dzne
700 1 _ |a Gardiol, Alejandra
|b 8
700 1 _ |a Boccardi, Marina
|0 P:(DE-2719)9000492
|b 9
|e Last author
773 _ _ |a 10.1186/s12967-024-05476-1
|g Vol. 22, no. 1, p. 693
|0 PERI:(DE-600)2118570-0
|n 1
|p 693
|t Journal of translational medicine
|v 22
|y 2024
|x 1479-5876
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP2.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/271064/files/DZNE-2024-00936.pdf
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP2.doc
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP2.odt
856 4 _ |u https://pub.dzne.de/record/271064/files/DZNE-2024-00936%20SUP2.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/271064/files/DZNE-2024-00936.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:271064
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002584
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002840
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002949
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9000492
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-20
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-20
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J TRANSL MED : 2022
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:07:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:07:28Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-20
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-20
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-20
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-20
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J TRANSL MED : 2022
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:07:28Z
920 1 _ |0 I:(DE-2719)5000062
|k AG Boccardi
|l Implementation Neuroscience
|x 0
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000062
980 _ _ |a I:(DE-2719)1510100
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21